Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Paratek Pharmaceuticals (PRTK) Share Price
Media headlines about Paratek Pharmaceuticals (NASDAQ:PRTK) have trended somewhat positive on Monday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.2674531093206 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Paratek For The Layman – Seeking Alpha (seekingalpha.com)
- These Pharma Executives Are Showing Their Cards (finance.yahoo.com)
- Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017 (finance.yahoo.com)
- Paratek Pharmaceuticals, Inc. (PRTK) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Robert W. Baird Reiterates “Buy” Rating for Paratek Pharmaceuticals, Inc. (PRTK) (americanbankingnews.com)
Several equities research analysts have recently weighed in on PRTK shares. Guggenheim started coverage on Paratek Pharmaceuticals in a report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 price objective for the company. Robert W. Baird reissued a “buy” rating and issued a $40.00 price objective on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Cantor Fitzgerald set a $50.00 price target on Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, July 17th. BidaskClub cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research cut Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $38.11.
Paratek Pharmaceuticals (PRTK) traded down 0.23% during midday trading on Monday, hitting $21.65. The stock had a trading volume of 312,523 shares. The stock has a 50-day moving average price of $24.46 and a 200 day moving average price of $22.89. Paratek Pharmaceuticals has a one year low of $9.80 and a one year high of $29.00. The firm’s market cap is $601.03 million.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million for the quarter, compared to analyst estimates of $7.50 million.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.